




The relative strengths and weaknesses of Virpax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Virpax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 6.9% points. The greatest weakness of Virpax Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 124%, being 89% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	9,628
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,694
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	500
Other Revenues	0
Property and Equipment	0
Research and Development	5,118
Selling, General and Administrative Expense	10,572

Output Variable	Value in 1000 USD
Assets	9,628
Liabilities	7,694
Expenses	15,690
Revenues	0
Stockholders Equity	1,934
Net Income	-15,190
Comprehensive Net Income	-15,190
BaseVar	16,756
ECR before Limited Liability	-127%
Economic Capital Ratio	124%